© WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Editorial Board Chairs: Antonello Mai, Rainer Metternich. Assoc. Editors: David Peralta, Scott Williams (Sr)
Impact Factor: 2.98
ISI Journal Citation Reports © Ranking: 2015: 18/59 (Chemistry Medicinal); 76/253 (Pharmacology & Pharmacy)
Online ISSN: 1860-7187
October 11, 2011
VIP: From Catalysts to Bioactive Organometallics: Do Grubbs Catalysts Trigger Biological Effects?
Luciano Oehninger, Hamed Alborzinia, Stephanie Ludewig, Knut Baumann, Stefan Wölfl, Ingo Ott*
The rapid progress in inorganic and organometallic chemistry over the last decades has also stimulated research in medicinal chemistry. As a consequence, novel structural elements for the development of metal-based drugs have emerged. In a collaborative research project led by Ingo Ott, scientists from the Institute of Medicinal and Pharmaceutical Chemistry at the Technische Universität Braunschweig (Germany) and the Institute of Pharmacy and Molecular Biotechnology at Ruprecht-Karls Universität in Heidelberg investigated the potential of Grubbs-type catalysts in medicinal chemistry.
Ott and his team evaluated the inhibition of several relevant enzymes, the effects on the proliferation of cultured tumor cells, as well as the influence on tumor cell metabolism. They demonstrated that some of the catalysts are able to trigger distinct biological effects related to cancer chemotherapy. Whereas the studied catalysts themselves may not be suitable as antitumor drug candidates, the incorporation of certain partial structures in future metal-based drugs appears to be particularly promising.
Received June 22, 2011; published online September 7, 2011, DOI: 10.1002/cmdc.201100308.